UBS Sees an Imminent Catalyst for Biogen (BIIB) PT Right Sized to $442
Tweet Send to a Friend
UBS analyst Colin Bristow lowered the price target on Biogen (NASDAQ: BIIB) to $442.00 (from $475.00) while maintaining a Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
